# A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)

> **NCT01025232** · PHASE1,PHASE2 · TERMINATED · sponsor: **David M. Brown, M.D.** · enrollment: 88 (actual)

## Conditions studied

- Age Related Macular Degeneration
- Choroidal Neovascular Membrane
- Subfoveal Neovascular Age-Related Macular Degeneration
- Macular Degeneration
- Wet Age-Related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01025232
- **Lead sponsor:** David M. Brown, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** The last remaining subject withdrew consent because the collaborator Genentech stopped supplying study drug.
- **Last updated:** 2017-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01025232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01025232, "A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01025232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*